177 lu-psma radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials

Finn E. von Eyben, Kalevi Kairemo, Channing Paller, Manuela Andrea Hoffmann, Giovanni Paganelli, Irene Virgolini, Giandomenico Roviello

Research output: Contribution to journal › Review article › peer-review

Fingerprint

Dive into the research topics of '177 lu-psma radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds